---
title: "The artemisinin sector sees a short-term surge, Rundu Pharma hits the limit up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233380307.md"
description: "The artemisinin sector saw a short-term surge, with Rundu Pharma hitting the limit-up, followed by gains in Baihua Medicine, HISUN, ZMC, Kunming Pharmaceutical Group, and CR Double-Crane"
datetime: "2025-03-27T02:58:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233380307.md)
  - [en](https://longbridge.com/en/news/233380307.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233380307.md)
generator: "portal-rs"
---

# The artemisinin sector sees a short-term surge, Rundu Pharma hits the limit up

The artemisinin sector saw a short-term surge, with Rundu Pharma hitting the limit up, followed by gains in Baihua Pharmaceutical, HISUN, ZMC, Kunming Pharmaceutical Group, and CR Double-Crane

### Related Stocks

- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)
- [600062.CN](https://longbridge.com/en/quote/600062.CN.md)
- [600267.CN](https://longbridge.com/en/quote/600267.CN.md)
- [002923.CN](https://longbridge.com/en/quote/002923.CN.md)
- [600422.CN](https://longbridge.com/en/quote/600422.CN.md)
- [600721.CN](https://longbridge.com/en/quote/600721.CN.md)

## Related News & Research

- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)
- [DHL partners local life sciences incubator to provide cold chain logistics for biotech startups](https://longbridge.com/en/news/298027232.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**